OPTN - オプティノ―ズ (OptiNose Inc.)

OPTNのニュース

   Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  2021/08/25 21:00:00 Intrado Digital Media
YARDLEY, Pa., Aug. 25, 2021 (GLOBE NEWSWIRE) -- OptiNose , Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted non-qualified stock option awards to purchase an aggregate of 60,000 shares of its common stock to seven new employees as an inducement material for accepting employment with OptiNose. The stock option awards were granted outside of the OptiNose, Inc. 2010 Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
   OptiNose EPS misses by $0.02, misses on revenue  2021/08/11 11:27:41 Seeking Alpha
   Optinose Reports Second Quarter 2021 Financial Results and Recent Operational Highlights  2021/08/11 11:00:00 Intrado Digital Media
Second quarter 2021 XHANCE net revenue of $18.4 million increased 79% compared to second quarter 2020
   Optinose Completes Patient Recruitment in Pivotal Trial for XHANCE in Chronic Sinusitis  2021/07/30 12:00:00 Intrado Digital Media
Company Expects Top-Line Results in First Quarter 2022
   Optinose Announces Preliminary Second Quarter 2021 XHANCE Net Revenue of $18.4 Million  2021/07/28 12:00:00 Intrado Digital Media
Preliminary XHANCE Net Revenue Growth of 79% Compared to Second Quarter 2020
   Optinose Completes Patient Recruitment in Pivotal Trial for XHANCE in Chronic Sinusitis  2021/07/30 12:00:00 Intrado Digital Media
Company Expects Top-Line Results in First Quarter 2022
   Optinose Announces Preliminary Second Quarter 2021 XHANCE Net Revenue of $18.4 Million  2021/07/28 12:00:00 Intrado Digital Media
Preliminary XHANCE Net Revenue Growth of 79% Compared to Second Quarter 2020
   Global Corticosteroid Nasal Spray Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Pfizer, Sanofi, Kurve Technology, Aegis Therapeutics, OptiNose, GlaxoSmithKline, Merck, Marina Biotech  2021/07/23 16:44:04 Jumbo News
The report on Global Corticosteroid Nasal Spray Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic []
   OptiNose: Growing Sales Make The Current Market Cap Look Very Low  2021/07/19 03:56:35 Seeking Alpha
   OptiNose Inc Shares Near 52-Week Low - Market Mover  2021/07/17 16:05:42 Kwhen Finance
OptiNose Inc (OPTN) shares closed today at 1.8% above its 52 week low of $2.80, giving the company a market cap of $151M. The stock is currently down 31.2% year-to-date, down 41.0% over the past 12 months, and down 85.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.0%. Trading Activity Trading volume this week was 51.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 227.0% The company's stock price performance over the past 12 months lags the peer average by 161.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Optinose Completes Patient Recruitment in Pivotal Trial for XHANCE in Chronic Sinusitis  2021/07/30 12:00:00 Intrado Digital Media
Company Expects Top-Line Results in First Quarter 2022
   Optinose Announces Preliminary Second Quarter 2021 XHANCE Net Revenue of $18.4 Million  2021/07/28 12:00:00 Intrado Digital Media
Preliminary XHANCE Net Revenue Growth of 79% Compared to Second Quarter 2020
   Global Corticosteroid Nasal Spray Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Pfizer, Sanofi, Kurve Technology, Aegis Therapeutics, OptiNose, GlaxoSmithKline, Merck, Marina Biotech  2021/07/23 16:44:04 Jumbo News
The report on Global Corticosteroid Nasal Spray Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic []
   OptiNose: Growing Sales Make The Current Market Cap Look Very Low  2021/07/19 03:56:35 Seeking Alpha
   OptiNose Inc Shares Near 52-Week Low - Market Mover  2021/07/17 16:05:42 Kwhen Finance
OptiNose Inc (OPTN) shares closed today at 1.8% above its 52 week low of $2.80, giving the company a market cap of $151M. The stock is currently down 31.2% year-to-date, down 41.0% over the past 12 months, and down 85.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.0%. Trading Activity Trading volume this week was 51.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 227.0% The company's stock price performance over the past 12 months lags the peer average by 161.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

calendar